Industry News
GammaDelta Therapeutics initiates first-in-human Phase 1 trial of GDX012 for the treatment of acute myeloid leukemia
First dose delivered to patients in a multi-center U.S. clinical trial to evaluate novel gamma-delta T cell cancer therapy